Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Equity Awards - Geron Corporation granted equity awards covering an aggregate of 966,000 shares of common stock, including stock options for 644,000 shares and restricted stock units (RSUs) for 322,000 shares to sixteen newly hired employees [1][2] - The stock options have an exercise price of $1.27 per share, equal to the closing price on the grant date, with a ten-year term and vesting over four years [2] - RSUs vest at a rate of 25% on each anniversary of the grant date, contingent on continued employment [2] Company Overview - Geron is a commercial-stage biopharmaceutical company focused on treating blood cancer, with its first-in-class telomerase inhibitor RYTELO® (imetelstat) approved in the US and EU for certain adult patients with lower-risk myelodysplastic syndromes [3] - The company is conducting a pivotal Phase 3 clinical trial of imetelstat for JAK-inhibitor relapsed/refractory myelofibrosis and other myeloid hematologic malignancies [3] - The mechanism of action involves inhibiting telomerase activity to reduce proliferation and induce death of malignant cells in the bone marrow [3]